Predicting the Severity of Acute Urinary Toxicity after Brachytherapy with Iodine-125 for Localized Prostate Cancer

Takeda, Ken; Jingu, K.; Koto, Masashi; Fujimoto, Keisuke; Narazaki, Kakutaro; Kubozono, Masaki; Saitō, Hideo; Yamada, Shigeyuki; Mitsuduka, K.; Ishidoya, Shigeto; Ariga, Hiroyoshi; Arai, Yoichi; Yamada, Satoshi

doi:10.1620/tjem.223.55

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thomas et al has reported a urethra grade 2 complication rate of 36% for plans with dosimetry similar to those used here in the original plans, which is consistent with our results 15 . Others have reported higher complication rates, 85–92%, for plans with dosimetry much higher the original plans presented here 16, 17 . However, these rates are consistent with those determined for plans with high initial seed strengths, seen in Figure 1.…”

Section: Discussionsupporting

confidence: 92%

“…15 Others have reported higher complication rates, 85À92%, for plans with dosimetry much higher the original plans presented here. 16,17 However, these rates are consistent with those determined for plans with high initial seed strengths, seen in Figure 1. The urethral response for the optimised plans is significantly lower than those of the original plans.…”

Section: Plansupporting

confidence: 85%

See 1 more Smart Citation

Inclusion of radiobiological factors in prostate brachytherapy treatment planning

et al. 2012

View full text Add to dashboard Cite

Purpose: Comparison of prostate seed implant treatment plans is currently based on evaluation of dose-volume histograms and doses to the tumour and normal structures. However, these do not account for effects of varying dose-rate, tumour repopulation and other biological effects. In this work, incorporation of the radiobiological response is used to obtain a more inclusive and clinically relevant treatment plan evaluation tool.Materials and Methods: Ten patients were evaluated. For each patient, six different treatment plans were created on the Prowess system. Plans with iodine-125 used a prescription dose of 145 Gy while plans with palladium-103 used 115 Gy. The biologically effective dose was used together with the tumour control probability and the normal tissue complication probabilities of urethra, bladder, rectum and surrounding tissue to evaluate the effectiveness of each treatment plan. Results from the radiobiological evaluation were compared to standard dose quantifiers.Results: The use of response probabilities is seen to provide a simpler means of treatment evaluation compared to standard dose quantifiers. This allows for different treatment plans to be quickly compared. Additionally, the use of radiobiologically-based plan evaluation allows for optimisation of seed type and initial seed strengths to find the ideal balance of TCP and NTCP.Conclusion: The goal of this work was to incorporate the biological response to obtain a more complete and clinically relevant treatment plan evaluation tool. This resulted in a simpler means of plan evaluation that may be used to compare and optimise prostate seed implant treatment plans.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Plansupporting

confidence: 85%

Inclusion of radiobiological factors in prostate brachytherapy treatment planning

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Takeda et al . has reported that for a patient cohort with average urethral D 90 = 150 Gy, 90% experienced RTOG grade 2 symptoms and 6.5% experienced grade 3 symptoms [34]. Additionally, Thomas et al .…”

Section: Discussionmentioning

confidence: 99%

Clinical Investigations Radiobiologically based treatment plan evaluation for prostate seed implants

Knaup

Mavroidis

Esquivel

et al. 2011

jcb

View full text Add to dashboard Cite

PurposeAccurate prostate low dose-rate brachytherapy treatment plan evaluation is important for future care decisions. Presently, an evaluation is based on dosimetric quantifiers for the tumor and organs at risk. However, these do not account for effects of varying dose-rate, tumor repopulation and other biological effects. In this work, incorporation of the biological response is used to obtain more clinically relevant treatment plan evaluation.Material and methodsEleven patients were evaluated. Each patient received a 145 Gy implant. Iodine-125 seeds were used and the treatment plans were created on the Prowess system. Based on CT images the post-implant plan was created. In the post-plan, the tumor, urethra, bladder and rectum were contoured. The biologically effective dose was used to determine the tumor control probability and the normal tissue complication probabilities for the urethra, bladder, rectum and surrounding tissue.ResultsThe average tumor control probability and complication probabilities for the urethra, bladder, rectum and surrounding tissue were 99%, 29%, 0%, 12% and 6%, respectively. These measures provide a simpler means for evaluation and since they include radiobiological factors, they provide more reliable estimation of the treatment outcome. ConclusionsThe goal of this work was to create more clinically relevant prostate seed-implant evaluation by incorporating radiobiological measures. This resulted in a simpler descriptor of treatment plan quality and was consistent with patient outcomes.

show abstract

Quantitative evaluation of lower urinary tract symptoms using a visual analog scale in men undergoing permanent brachytherapy

Okihara¹,

Ukimura²,

Ushijima³

et al. 2012

Brachytherapy

View full text Add to dashboard Cite

Predicting the Severity of Acute Urinary Toxicity after Brachytherapy with Iodine-125 for Localized Prostate Cancer

Cited by 5 publications

References 25 publications

Inclusion of radiobiological factors in prostate brachytherapy treatment planning

Inclusion of radiobiological factors in prostate brachytherapy treatment planning

Clinical Investigations Radiobiologically based treatment plan evaluation for prostate seed implants

Quantitative evaluation of lower urinary tract symptoms using a visual analog scale in men undergoing permanent brachytherapy

Contact Info

Product

Resources

About